Trial Profile
A Multi-centre, Double-blind, Parallel-group, Randomised Controlled Study to Investigate Efficacy, Safety and Tolerability of Orally Administered BI 409306 During a 12-week Treatment Period Compared to Placebo in Patients With Cognitive Impairment Due to Alzheimer's Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Osoresnontrine (Primary) ; Donepezil
- Indications Alzheimer's disease; Cognition disorders
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim; Unilfarma
- 09 Feb 2018 According to a Boehringer Ingelheim media release, data will be presented at the Alzheimer's Association International Conference (AAIC) in July 2018.
- 18 Jan 2018 Status changed from active, no longer recruiting to completed.
- 18 Dec 2017 This trial was completed in Portugal (2017-10-10), according to European Clinical Trials database.